145 related articles for article (PubMed ID: 15232337)
1. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia.
Wonodi I; Adami H; Sherr J; Avila M; Hong LE; Thaker GK
J Clin Psychopharmacol; 2004 Aug; 24(4):441-5. PubMed ID: 15232337
[TBL] [Abstract][Full Text] [Related]
2. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.
Thaker GK; Nguyen JA; Strauss ME; Jacobson R; Kaup BA; Tamminga CA
Am J Psychiatry; 1990 Apr; 147(4):445-51. PubMed ID: 1969244
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
4. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.
Emsley R; Niehaus DJ; Koen L; Oosthuizen PP; Turner HJ; Carey P; van Rensburg SJ; Maritz JS; Murck H
Schizophr Res; 2006 May; 84(1):112-20. PubMed ID: 16632329
[TBL] [Abstract][Full Text] [Related]
5. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Pappa S; Tsouli S; Apostolou G; Mavreas V; Konitsiotis S
Clin Neuropharmacol; 2010; 33(6):271-5. PubMed ID: 21121175
[TBL] [Abstract][Full Text] [Related]
6. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
Lerner V; Miodownik C; Kaptsan A; Bersudsky Y; Libov I; Sela BA; Witztum E
J Clin Psychiatry; 2007 Nov; 68(11):1648-54. PubMed ID: 18052557
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
8. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
Soares KV; McGrath JJ; Deeks JJ
Cochrane Database Syst Rev; 2001; (2):CD000203. PubMed ID: 11405955
[TBL] [Abstract][Full Text] [Related]
9. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
10. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
Soares-Weiser K; Rathbone J
Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
[TBL] [Abstract][Full Text] [Related]
11. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.
Caroff SN; Walker P; Campbell C; Lorry A; Petro C; Lynch K; Gallop R
J Clin Psychiatry; 2007 Mar; 68(3):410-5. PubMed ID: 17388711
[TBL] [Abstract][Full Text] [Related]
12. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
Goff DC; Renshaw PF; Sarid-Segal O; Dreyfuss DA; Amico ET; Ciraulo DA
Biol Psychiatry; 1993 May; 33(10):700-6. PubMed ID: 8102552
[TBL] [Abstract][Full Text] [Related]
14. Clonazepam and phenobarbital in tardive dyskinesia.
Bobruff A; Gardos G; Tarsy D; Rapkin RM; Cole JO; Moore P
Am J Psychiatry; 1981 Feb; 138(2):189-93. PubMed ID: 6109454
[TBL] [Abstract][Full Text] [Related]
15. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
Soares KV; McGrath JJ; Deeks JJ
Cochrane Database Syst Rev; 2000; (2):CD000203. PubMed ID: 10796320
[TBL] [Abstract][Full Text] [Related]
16. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
McGrath JJ; Soares KV
Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
18. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
19. Treatment of tardive dyskinesia with donepezil: a pilot study.
Caroff SN; Campbell EC; Havey J; Sullivan KA; Mann SC; Gallop R
J Clin Psychiatry; 2001 Oct; 62(10):772-5. PubMed ID: 11816865
[TBL] [Abstract][Full Text] [Related]
20. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
Shamir E; Barak Y; Shalman I; Laudon M; Zisapel N; Tarrasch R; Elizur A; Weizman R
Arch Gen Psychiatry; 2001 Nov; 58(11):1049-52. PubMed ID: 11695951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
